An experimental therapy that until recently had only been tested on mice and monkeys has now been given to a human patient in the United States. The treatment, known as ER-100, was administered as an injection into a single eye as part of a clinical study. It aims to treat glaucoma and other conditions that can lead to loss of vision.
The therapy is being developed by an American company and represents an early step in a closely watched area of medicine. Moving from animal testing to a human trial marks a significant moment for the research, which had previously been limited to studies in mice and monkeys. The shift to people is being approached with caution.
In this first stage, the treatment is delivered directly into one eye of the patient. The clinical study is designed to assess how the therapy behaves in humans and whether it is safe. The focus at this point is on safety rather than on proving that the treatment works.
Over the next six months, the patient will be kept under observation. Researchers will monitor for any possible adverse effects during that period. This monitoring window is intended to catch any problems early and to build an understanding of how the body responds to the therapy.
The initial clinical trial of ER-100, which has been approved by US authorities, is expected to involve close to 20 patients. The relatively small number reflects the early and cautious nature of the research. Each participant will help researchers gather data on the treatment's safety and tolerability.
The broader idea behind the therapy, cellular reprogramming, has drawn considerable attention and money in recent years. The field has attracted significant investment from prominent billionaires and from well-known pharmaceutical companies. Specialists say the potential of the approach is enormous, which helps explain the level of interest it has generated.
At the same time, the research carries notable risks. One of the biggest concerns is the possibility of cancer, because in some experiments on mice, cellular reprogramming was associated with the appearance of cancerous growths. For now, the work remains at an early stage, and researchers are staying cautious as the first human results are awaited.